Home » Newsletters » BioWorld Science

BioWorld Science

May 5, 2017

View Archived Issues

Bristol-Myers Squibb offers pipeline update of first quarter 2017

AstraZeneca updates regulatory and clinical progress of first quarter 2017

Vivet Therapeutics closes series A financing round

Lundbeck describes brain-penetrant PDE1 inhibitors for cognitive disorders

NIH grant supports Spero's preclinical development of SPR-720 for TB

FDA awards new designations to three Sangamo programs

Saniona participates in formation of Scandion Oncology

OncoMed initiates phase Ia study of OMP-313M32 in advanced solid tumors

FLX-787 demonstrates clinical benefit for treating nocturnal leg cramping

Celsion reports new data from OVATION study of GEN-1 in ovarian cancer

Polymorphism in TDP1 associated with poor survival in SCLC patients

Zafgen reports phase I topline data on ZGN-1061

ImMAGE Biotherapeutics begins repeat toxicology study for IMT-001

Galapagos identifies IRAK-4 inhibitors

Rhythm advances setmelanotide program into phase III for pro-opiomelanocortin deficiency obesity

Otsuka Pharmaceutical patents MAPK3 and MAPK1 inhibitors

Cardioxyl Pharmaceuticals divulges nitroxyl donors

ISIS-581088/AZD-5363 studies target the androgen receptor and AKT kinase in prostate cancer

Array BioPharma discovers FGFR tyrosine kinases inhibitors

Aplidin granted orphan drug designation in Switzerland for multiple myeloma

Shanghai Institute Materia Medica and Sunnylife Pharma patent BTK inhibitors

ADC Therapeutics enrolling patients in phase I trial of ADCT-502

Dauntless Pharmaceuticals reports promising phase I results for intranasal octreotide acetate

MDxHealth and Maastricht University expand research collaboration

Commense signs licensing agreement with UBC for microbiome-based therapy to prevent asthma

Compound shows promise in vivo for heart failure therapy

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...